Emerald Mutual Fund Advisers Trust Sells 328,407 Shares of Insmed, Inc. $INSM

Emerald Mutual Fund Advisers Trust lessened its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 92.8% during the second quarter, Holdings Channel.com reports. The fund owned 25,424 shares of the biopharmaceutical company’s stock after selling 328,407 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Insmed were worth $2,559,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. M&T Bank Corp increased its stake in Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock worth $252,000 after acquiring an additional 147 shares during the period. ORG Partners LLC increased its stake in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares during the period. Cullen Frost Bankers Inc. increased its stake in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 221 shares during the period. Nisa Investment Advisors LLC increased its stake in Insmed by 6.5% during the 1st quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 228 shares during the period. Finally, Hilltop National Bank bought a new position in Insmed during the 2nd quarter worth $28,000.

Analysts Set New Price Targets

INSM has been the topic of a number of recent research reports. Royal Bank Of Canada raised their price objective on Insmed from $108.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Jefferies Financial Group raised their target price on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. Morgan Stanley raised their target price on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Stifel Nicolaus raised their target price on Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Finally, UBS Group raised their target price on Insmed from $140.00 to $194.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $161.59.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares of the company’s stock, valued at $13,477,168.46. This trade represents a 19.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the firm’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at approximately $5,303,252.45. This trade represents a 67.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 152,657 shares of company stock worth $21,442,198 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

Insmed Trading Up 1.0%

Shares of INSM stock opened at $166.95 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $168.21. The company has a market cap of $35.29 billion, a PE ratio of -29.24 and a beta of 1.03. The stock’s fifty day moving average price is $149.63 and its two-hundred day moving average price is $110.68.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same period last year, the business earned ($1.94) EPS. The company’s revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Equities analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.